| The Centers for Medicare & Medicaid Services (CMS) will publish the Calendar Year (CY) 2027 Physician Fee Schedule (PFS) final rule, which is expected to finalize significant proposed changes to remote patient monitoring (RPM) and remote therapeutic monitoring (RTM) reimbursement policies. | Final rule publication in November 2026; effective January 1, 2027. | 2026-11-01 | 2027-01-01 | This catalyst is critical as the proposed changes, including requiring RPM/RTM services to be furnished by direct employees and potentially consolidating CPT codes, could fundamentally alter the operational and financial models for companies providing remote monitoring solutions. It directly impacts the reimbursement landscape for wearable health devices. | Theme | theme_composer | DXCM, IRTC, MYO | 3 | 0.001 | 1.18 | 1.0 | | 1.0 | 0.1129 | 2026-08-06 | False | 1 | 0.4085 | 48.1984 | | Theme composer | | |
| Pharmaceutical companies (e.g., Novo Nordisk, Eli Lilly) will release Q3 and Q4 2026 earnings, providing updated prescription volume data and sales figures for GLP-1 medications, alongside anticipated FDA approvals and launches of new GLP-1 drugs like Novo Nordisk's CagriSema (late 2026) and Boehringer Ingelheim's survodutide (H1 2027). | October-November 2026 (Q3 earnings), Q1 2027 (Q4 earnings and new drug launches). | 2026-10-01 | 2027-03-31 | The continued rapid adoption and expansion of GLP-1 therapies, particularly oral formulations and new market entrants, pose a significant substitution risk for continuous glucose monitoring (CGM) demand, directly impacting companies like Dexcom (DXCM). | Theme | theme_composer | DXCM | 1 | 0.0008 | 1.18 | 0.92 | Regulatory/Policy | 1.35 | 0.1149 | 2026-08-06 | False | 1 | 0.0075 | 1.1014 | | Theme composer | | |
| Potential Medicare coverage expansion for Libre Continuous Glucose Monitoring (CGM) for Type 2 non-insulin users in the US. | in the fall | 2026-09-01 | 2026-11-30 | This could unlock a multibillion-dollar opportunity by accelerating commercial insurance coverage and reaching approximately 10 million Medicare beneficiaries, significantly boosting CGM sales. | Ticker | | | | | | | | | | | | | | | earnings_transcript | ABT (ticker) | ABT_79370e41 | 2026-07-16 |
| FDA approval and US launch of Amulet 360 Left Atrial Appendage (LAA) device. | by year-end 2026 | 2026-10-01 | 2026-12-31 | This device is designed to help reduce the risk of stroke in patients with AFib and is expected to reignite growth and capture market share in the LAA closure market. | Ticker | | | | | | | | | | | | | | | earnings_transcript | ABT (ticker) | ABT_30e24e43 | 2026-10-21 |
| Broad U.S. launch of TactiFlex Duo catheter. | starting in the fourth quarter | 2026-10-01 | 2026-12-31 | This catheter enables physicians to seamlessly switch between using RF and PFA energy during a procedure, which is expected to drive adoption and market share in electrophysiology. | Ticker | | | | | | | | | | | | | | | earnings_transcript | ABT (ticker) | ABT_7cc559f2 | 2026-10-21 |
| Launch of Volt PFA catheter in Japan. | sometime in Q4 | 2026-10-01 | 2026-12-31 | This launch is expected to turn Japan from a headwind to a tailwind for the electrophysiology business, contributing to international growth acceleration. | Ticker | | | | | | | | | | | | | | | earnings_transcript | ABT (ticker) | ABT_8bb43b0e | 2026-10-21 |
| CMS to publish the CY 2027 Physician Fee Schedule final rule, finalizing changes to remote patient monitoring (RPM) and remote therapeutic monitoring (RTM) reimbursement policies. | Final rule publication in November 2026; effective January 1, 2027. | 2026-11-01 | 2027-01-01 | This rule could significantly alter the operational and financial models for companies providing remote monitoring solutions, directly impacting the reimbursement landscape for wearable health devices including Dexcom's offerings. | Theme | | | | | | | | | | | | | | | earnings_transcript | DXCM (ticker) | DXCM_80554779 | 2026-07-30 |
| CMS decision on coverage expansion for Type 2 non-insulin diabetes patients, following the submission of Connect trial data. | before the end of this year | 2026-08-07 | 2026-12-31 | This decision has the potential to significantly expand the addressable market for Dexcom CGM in the US, impacting 25 million Type 2 non-insulin customers. | Ticker | | | | | | | | | | | | | | | earnings_transcript | DXCM (ticker) | DXCM_e0606eaf | 2026-07-30 |
| Dexcom expects to convert nearly 50% of its US customer base to the G7 15-day system. | by year end | 2026-10-01 | 2026-12-31 | This conversion is translating into stronger customer satisfaction and is expected to contribute to improved gross margins. | Ticker | | | | | | | | | | | | | | | earnings_transcript | DXCM (ticker) | DXCM_b887655c | 2026-07-30 |
| European commercial launch of MiniMed Flex. | November of this year | 2026-11-01 | 2026-11-30 | This launch follows CE Mark approval and is expected to drive strong growth in international markets by expanding reach into new patients and increasing competitive conversions. | Ticker | | | | | | | | | | | | | | | earnings_transcript | MMED (ticker) | MMED_99ed2845 | 2026-09-01 |
| Transition to direct commercial operations in additional key European markets, following the playbook from initial transitions. | in the fourth quarter | 2026-10-01 | 2026-12-31 | Expected to improve price and margins (ASP premiums at least 30% higher) and deepen relationships, but also involves an anticipated $15 million headwind from distributor destocking and inventory buybacks for 2026. | Ticker | | | | | | | | | | | | | | | earnings_transcript | TNDM (ticker) | TNDM_709c0ea7 | 2026-02-20 |
| FDA clearance for Mobi Tubeless, enabling its commercial launch. | second half of the year | 2026-07-01 | 2026-12-31 | Regulatory approval is necessary to launch this significant new product, which is Tandem's first patch pump and the world's first with extended wear technology, potentially impacting market share and revenue. | Ticker | | | | | | | | | | | | | | | earnings_transcript | TNDM (ticker) | TNDM_82e30c2b | 2026-02-20 |
| Commercial launch of Mobi Tubeless, a novel infusion site option for the Mobi pump that transforms it into a tubeless patch device. | second half of the year | 2026-07-01 | 2026-12-31 | Introduces a new form factor and technology, potentially expanding Tandem's addressable market and competitive position against patch pump competitors, though not included in 2026 revenue guidance. | Ticker | | | | | | | | | | | | | | | earnings_transcript | TNDM (ticker) | TNDM_a7005c10 | 2026-02-20 |
| Initiation of a pivotal trial for Tandem's fully closed-loop automated insulin delivery algorithm. | later this year | 2026-07-01 | 2026-12-31 | A crucial step towards developing a next-generation AID system, aiming for FDA filing in 2027, which is vital for maintaining Tandem's leadership in AID innovation. | Ticker | | | | | | | | | | | | | | | earnings_transcript | TNDM (ticker) | TNDM_8eea9c45 | 2026-02-20 |
| U.S. launch of Libre Duo, the world's first dual glucose ketone biowearable sensor. | in December | 2026-12-01 | 2026-12-31 | This product allows people with diabetes to monitor ketones without traditional blood or urine tests, offering a new growth driver for the diabetes care business. | Ticker | | | | | | | | | | | | | | | earnings_transcript | ABT (ticker) | ABT_6009f906 | 2026-10-21 |
| The Centers for Medicare & Medicaid Services (CMS) is introducing a new "Software as a Medical Service" payment framework for algorithm-driven technologies in its Calendar Year (CY) 2027 payment rules, alongside ongoing updates and clarifications from the FDA regarding its AI framework and digital health guidance. | January 1, 2027 (CMS framework effective date), ongoing throughout 2026-2027 (FDA guidance updates). | 2027-01-01 | 2027-12-31 | This catalyst provides a clearer regulatory and reimbursement pathway for AI-enhanced wearable platforms, potentially accelerating adoption and market entry for innovative diagnostic and monitoring solutions, benefiting companies integrating AI into their devices. | Theme | theme_composer | IRTC, MYO, DXCM | 3 | 0.0011 | 1.18 | 0.92 | Regulatory/Policy | 1.35 | 0.1617 | 2026-08-06 | False | 1 | 0.4085 | 59.8624 | | Theme composer | | |
| Significant U.S. payer formulary coverage for Libre goes into effect. | January 1 | 2027-01-01 | 2027-01-01 | This expanded coverage is expected to be a nice growth driver for the diabetes business in the coming year. | Ticker | | | | | | | | | | | | | | | earnings_transcript | ABT (ticker) | ABT_c375ff52 | 2026-10-21 |
| Regulatory filing for Insulet's fully closed-loop system for Type 2 diabetes. | supporting a regulatory filing in 2027 | 2027-01-01 | 2027-12-31 | Successful regulatory filing is a prerequisite for commercial launch, enabling Insulet to access the vast and underpenetrated Type 2 diabetes market with a highly differentiated product, impacting future revenue and valuation. | Ticker | | | | | | | | | | | | | | | earnings_transcript | PODD (ticker) | PODD_5dda514d | 2026-02-18 |
| Commercial launch of Insulet's next-generation Omnipod 6 system. | accelerate our innovation cycle as we prepare for launch in 2027 | 2027-01-01 | 2027-12-31 | This next-gen platform is designed to offer improved connectivity, flexibility, and personalized automation, crucial for maintaining competitive leadership and driving future revenue growth and investor sentiment. | Ticker | | | | | | | | | | | | | | | earnings_transcript | PODD (ticker) | PODD_93a0b76a | 2026-02-18 |
| The Heart Rhythm Society's annual meeting, Heart Rhythm 2027, will gather the global electrophysiology community to discuss groundbreaking science, clinical education, and innovations in cardiac pacing and electrophysiology. | May 13-16, 2027. | 2027-05-13 | 2027-05-16 | This conference is crucial for companies in cardiac monitoring, as it showcases new research, product developments, and discussions on digital health and innovation relevant to wearable heart monitors and diagnostic devices. | Theme | theme_composer | IRTC | 1 | 0.0001 | 1.18 | 1.05 | Conference/Council | 1.2 | 0.0133 | 2026-08-06 | False | 1 | 0.0009 | 0.1392 | | Theme composer | | |
| Full U.S. launch of MiniMed Fit, a patch pump. | by summer next year | 2027-06-01 | 2027-08-31 | Fit brings MiniMed's differentiated therapy platform to the fastest-growing segment of the insulin pump market, expanding reach into new patients and driving competitive conversions. | Ticker | | | | | | | | | | | | | | | earnings_transcript | MMED (ticker) | MMED_21687391 | 2026-09-01 |
| The 87th American Diabetes Association (ADA) Scientific Sessions will convene, bringing together professionals to share the latest developments in diabetes research, prevention, and care. | June 18-21, 2027. | 2027-06-18 | 2027-06-21 | This major conference is a key platform for presenting new clinical data, technological advancements, and policy discussions related to diabetes management, directly impacting companies involved in continuous glucose monitoring and other diabetes-focused wearable health solutions. | Theme | theme_composer | DXCM | 1 | 0.0008 | 1.18 | 1.05 | Regulatory/Policy, Conference/Council | 1.62 | 0.1705 | 2026-08-06 | False | 1 | 0.0075 | 1.5085 | | Theme composer | | |
| Commercial launch of Insulet's fully closed-loop system for people with Type 2 diabetes. | a commercial launch in 2028 | 2028-01-01 | 2028-12-31 | This system is designed to make AID accessible to virtually everyone with Type 2 diabetes, significantly expanding the addressable market and driving future growth, potentially solidifying Insulet's leadership in this segment. | Ticker | | | | | | | | | | | | | | | earnings_transcript | PODD (ticker) | PODD_fdc63d7d | 2026-02-18 |
| Insulet's new manufacturing facility in Costa Rica becomes operational. | expected to be operational in 2029 | 2029-01-01 | 2029-12-31 | This investment in capacity and automation is critical for supporting long-term industry-leading growth and achieving continued margin expansion, impacting profitability and valuation. | Ticker | | | | | | | | | | | | | | | earnings_transcript | PODD (ticker) | PODD_55d4bc0d | 2026-02-18 |